Irinotekan Accord (Irinotecan Hydrochloride Trihydrate)

Irinotecan Hydrochloride Trihydrate, the active ingredient in Irinotekan Accord, is a topoisomerase I inhibitor presented as a sterile intravenous solution for intravenous use. It is employed in the treatment of colorectal cancer and metastatic colorectal cancer in adult patients.

GNH USA supplies Irinotekan Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Irinotecan is a chemotherapy agent that targets the topoisomerase I pathway in colorectal malignancies. It is indicated for the following conditions: - Colorectal cancer: used as part of combination regimens to reduce tumor burden and improve response rates. - Metastatic colorectal cancer: administered to extend survival and control disease progression in advanced stages.

Irinotecan may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Diarrhea: may be severe and require supportive care. - Nausea and vomiting: often managed with anti‑emetics. - Neutropenia: reduced white blood cell count increasing infection risk. - Alopecia: hair loss during treatment cycles. - Fatigue: generalized tiredness. - Abdominal cramping.

Serious or Rare Side Effects: - Severe neutropenia with fever (febrile neutropenia). - Life‑threatening colitis or severe diarrhea. - Elevated liver enzymes indicating hepatic injury. - Allergic reactions including anaphylaxis. - Pulmonary toxicity such as interstitial pneumonitis. - Hemorrhagic events due to thrombocytopenia.

Before initiating therapy, clinicians should assess baseline health status and monitor patients closely for known risks. - Blood count monitoring: regular CBC to detect neutropenia. - Liver function assessment: evaluate transaminases before and during treatment. - Renal function evaluation: adjust dosing if renal impairment is present. - Hypersensitivity avoidance: discontinue if severe allergic reaction occurs. - Anti‑diarrheal prophylaxis: consider loperamide to mitigate severe diarrhea. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Irinotecan can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin) may markedly reduce irinotecan exposure. - Concurrent myelosuppressive agents increase risk of severe bone‑marrow suppression. - Anticholinergic drugs can exacerbate irinotecan‑induced diarrhea. - Live vaccines are contraindicated during treatment. - High‑dose warfarin may potentiate bleeding risk.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., fluconazole) may increase SN‑38 levels. - UGT1A1 inhibitors can raise toxicity risk; dose adjustments may be needed. - Other chemotherapy agents may require schedule coordination to avoid overlapping toxicities. - Radiotherapy combined with irinotecan may heighten tissue damage. - Use of growth‑factor support (e.g., G‑CSF) should be monitored for synergistic effects.